Apyx MedicalvsJohnson & Johnson

APYX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

APYX

Apyx Medical Corporation

$2.65

Value $111M

-5.69%
APYX's page

Apyx Medical (APYX) has a market value of $111M and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, APYX moved -32.1% and JNJ +47.5%. Dividend yield: APYX none, JNJ 1.87%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    APYX$111M

    JNJ$681B

    JNJ is 6,143 times APYX

  • Revenue, 12 months

    APYX$60M

    JNJ$99.3B

    JNJ is 1,668 times APYX

  • Net income, 12 months

    APYX-$8.4M

    JNJ$16.1B

  • Operating margin

    APYX-5.5%

    JNJ–

  • ROIC

    APYX-5.7%

    JNJ12.4%

    18.0 points apart

  • P/E

    APYX–

    JNJ42.3

  • Dividend yield

    APYX0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    APYX-83.7%

    JNJ+98.6%

    182.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

APYX-83.7%

JNJ+98.6%

010020020222023202420252026
Returns by period
PeriodAPYXWith dividendsJNJWith dividends
1 year since November 14, 2025-32.1%Price -32.1%+47.5%Price +44.2%
3 years since November 16, 2023+26.8%+8.2% a yearPrice +26.8%+105.0%+27.0% a yearPrice +88.2%
5 years since November 15, 2021-83.7%-30.5% a yearPrice -83.7%+98.6%+14.7% a yearPrice +72.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

APYXApyx MedicalJNJJohnson & Johnson

Valuation

APYXJNJ
Valuation
Price$2.65$282.55
Market value$111M$681B
Enterprise value (EV)–$708B
P/E–42.3
P/E, 5-year median–21.9
P/B11.58.4
EV/EBIT–39.9
Free cash flow yield–3.0%

Results and growth

APYXJNJ
Results and growth
Revenue, 12 months$60M$99.3B
Net income, 12 months-$8.4M$16.1B
Free cash flow, 12 months-$8.9M$20.6B
Earnings per share, 12 months-$0.19$6.59
Revenue growth, year on year9.9%6.1%
Revenue growth a year, past+13.8%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

APYXJNJ
Margins and returns on capital
Gross margin63.4%67.6%
Operating margin-5.5%–
Net margin-14.2%16.2%
ROIC-5.7%12.4%
ROE-78.8%19.7%

Balance sheet

APYXJNJ
Balance sheet
Cash$26M$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover-0.6×18.0×

Dividends and buybacks

APYXJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: APYX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Apyx Medical or Johnson & Johnson?

By market value, Johnson & Johnson ($681B) is about 6,142.8 times Apyx Medical ($111M), at today's prices.

How did APYX and JNJ stock do over the last 5 years?

Since November 15, 2021, APYX's price moved -83.7% and JNJ's +72.8%. With dividends: APYX -83.7% (-30.5% a year), JNJ +98.6% (+14.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, APYX or JNJ?

The dividend yield at today's price is none for Apyx Medical and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Apyx Medical or Johnson & Johnson?

Over the last twelve months, the net margin was -14.2% for Apyx Medical and 16.2% for Johnson & Johnson, and the operating margin -5.5% and –. Revenue was $60M and $99.3B.

Which is the better investment, Apyx Medical or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.